HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

SNN

Smith & Nephew plc (NYSE)

Healthcare — Medical Devices

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

None 5 analysts
$29.60
+$0.87 (+3.03%)
Target: $34.99 (18.2%)
Sign in to add SNN to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$12.48B
P/E Ratio (TTM)20.66
Forward P/E13.69
EPS (TTM)$1.43
Dividend Yield2.72%
Profit Margin10.14%
Revenue Growth7.40%
ROE11.84%
Debt/Equity62.90
Recommendation None
Analyst Target$34.99
Analysts5
Indexes NYSE

Technical Indicators

RSI (14)39.6
Beta0.67
SMA 20-
SMA 40-
52-Week High$38.79
52-Week Low$28.56
50-Day Avg$30.43
200-Day Avg$33.29
Avg Volume$1.27M
Volume27.8K

Performance Analysis

NEUTRAL

SNN presents a mixed picture with both positive and negative indicators.

~ Trading at 10% of its 52-week range.
~ RSI at 39.6 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 7.4% year-over-year.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $34.99 implies 18.2% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:32 UTC

Back to Screener Export Report